Recurrent Melanoma Completed Phase 2 Trials for Selumetinib (DB11689)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00866177MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV MelanomaTreatment